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012.09.00Abstract Aim of the work: To study the prevalence of anti-HCV antibodies among patients suf-
fering from systemic lupus erythematosus (SLE) as well as to determine the impact of chronic HCV
infection on the clinical manifestations and disease activity.
Patients and methods: Ninety-eight consecutive SLE patients presented to the rheumatology
department, Cairo University Hospitals were included in the study. All patients were screened
for anti-HCV antibodies using a 3rd generation enzyme-linked immune-sorbent assay (ELISA).
Patients with positive anti-HCV were tested for the presence of HCV-RNA by polymerase chain
reaction (PCR). Patients were classiﬁed into two groups; HCV/SLE and non-HCV/SLE according
to the presence or absence of anti-HCV antibodies.
Results: Twenty/98 patients (20.4%) were positive for HCV antibody. Eight/98 patients (8.2%)
had active viremia. SLE patients with positive anti-HCV antibodies tend to be older in age and hav-
ing a longer SLE duration than non-HCV/SLE Patients. HCV/SLE patients had signiﬁcantly lower
mucocutaneous manifestations (p< 0.05) and higher cardiac manifestations and fundus abnormal-
ities (p< 0.04, p< 0.01 respectively) than non-HCV/SLE patients. There was no statistical differ-
ence between the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score between
both groups. Patients with HCV/SLE were less frequently on oral steroids than patients with non-
HCV/SLE.5237617.
m (W. Gaber).
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10 A. El Garf et al.Conclusion: HCV antibodies and active HCV viremia were found in 20.4% and 8.2% respec-
tively among SLE patients. SLE with positive anti-HCV antibodies tend to be older in age and hav-
ing longer SLE disease duration, lower mucocutaneous and higher cardiac manifestations and
fundus abnormalities. Concomitant chronic HCV infection has no adverse impact on SLEDAI.
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Hepatitis C virus (HCV), an enveloped positive, linear, single-
stranded RNA virus of the genus Hepacivirus and family
Flavivirdae, was identiﬁed in 1989 and recognized as the major
cause of non-A, non-B hepatitis [1]. HCV became a major pub-
lic health problem, with 170 million people infected worldwide
[2]. Egypt has possibly the highest HCV prevalence in the
world; antibody to HCV (anti-HCV) is present in 11–14% or
8–10 million inhabitants, of whom 5–7 million have active vire-
mia [3,4]; compared to the prevalence of antibodies to HCV in
the United States which is approximately 1.6% according to
the National Health and Nutrition Examination Survey [5].
The rate of infection varies among the different governorates
in Egypt; it is lowest in Cairo and Alexandria at 8%, interme-
diate in rural areas along the Nile south of Cairo (Middle and
Upper Egypt) at 8–16%, and highest in rural areas of Nile Del-
ta or Lower Egypt, at 15% [4]. In a recent study, HCV anti-
bodies were found in 18.5% among admitted patients to the
rheumatology ward, Cairo University Hospitals, Egypt. The
rheumatic manifestations of chronic HCV represent the pri-
mary cause of admission in 7% of all the admitted patients
in that department [6].
Systemic lupus erythematosus (SLE) is one of the common
rheumatic diseases in rheumatology practice, and the associa-
tion between two common diseases; chronic HCV infection
and SLE may occur. Whether, there is increased prevalence of
HCV infection in patients with SLE is still controversial. Anti-
bodies to HCV were present in 18/134 Spanish patients with
SLE (13%) compared to 2/200 (1%) of the blood donors studied
in the same geographic area. Among the anti-HCV-positive
group, HCV infection was conﬁrmed (by RIBA-3 and PCR)
in 15 SLE patients (11%) and in the 2 blood donors (1%)
(p< 0.001) [7]. Thirteen of 92 SLE patients were HCV positive,
while only 2 of the 58 normal controls were positive in China [8].
In a cross sectional study in Rio de Janeiro, Brazil; HCV
antibodies screening showed a signiﬁcant difference between
SLE patients and a blood donor control group (6.6% and
1.39% respectively). However, when conﬁrmatory assays were
subsequently applied, no difference in HCV prevalence between
both groups was observed [9]. The prevalence of antibodies
against HCV and HBV in SLE was not higher than in blood
donors or general population in Mexico and Israel [10,11].
Various mechanisms were proposed to explain the associa-
tion between HCV and SLE or autoimmunity in general. Out
of these, viruses have been postulated as a potential etiologic
or triggering agent in the pathogenesis of SLE. Persistent
HCV infection can evoke autoimmune response including the
production of autoantibodies through the ‘‘molecular mim-
icry’’ between HCV poly-proteins and self-proteins [12]. An-
other possible mechanism is ‘‘bystander activation’’ which
proposes that the viral infection can induce local tissueinﬂammation resulting in the activation of auto-reactive T-
cells that were dormant or suppressed by the peripheral regu-
latory mechanisms [13]. HCV-related autoimmunity has partly
been shown to be related to the increased serum B-lymphocyte
activating factor (BAFF) and/or the resistance of CD5+ B-
cells subpopulation to apoptosis in chronic HCV infection
[14,15].
The aim of this work was to determine the prevalence of
HCV infection in a cohort of patients with SLE, and to iden-
tify the impact of its presence on the clinical, laboratory and
immunologic features of the disease.2. Patients and methods
2.1. Study population
A total of 98 consecutive SLE patients (87 females and 11
males; mean age 26.5 years, range 14–63 years; mean disease
duration 4 years, range 0.25–17 years) presenting to the rheu-
matology department of Cairo University Hospitals were in-
cluded in this study. All patients fulﬁlled the 1982 revised
criteria of the American College of Rheumatology (ACR)
for the classiﬁcation of SLE [16]. All patients underwent a
medical interview through a preset questionnaire including
the detailed demographic data, medical history as well as a
routine examination by a qualiﬁed rheumatologist. All pa-
tients were screened for HCV antibodies and conﬁrmatory
quantitative PCR testing was done for all the HCV antibody
positive patients. Patients were classiﬁed into two groups
according to the presence of HCV antibodies: HCV/SLE
and non-HCV/SLE patients. The clinical and serologic charac-
teristics of all patients were documented. Disease activity was
assessed using the Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) [17]. The Ethics Committee of the
Faculty of Medicine, Cairo University; approved the study
and a written informed consent was obtained from each
participant.
2.2. Laboratory studies
Detection of HCV infection: All patients were screened for
anti-HCV antibodies using a 3rd generation enzyme-linked
immunosorbent assay (ELISA) (Innotest HCV Ab III, Innoge-
netics, Ghent, Belgium). All patients with positive anti-HCV
were tested for the presence of HCV RNA by polymerase
chain reaction (PCR; RNA extraction, reverse transcription
and polymerase chain reaction with primers complementary
to the 5’ non-coding region of the HCV genome).
Other laboratory tests: Routine laboratory investigations
were done including sedimentation rate (Westergren method),
complete blood picture, total plasma protein, serum albumin,
Table 1 Demographic data of the two groups.
HCV/SLE Non-HCV/SLE p-Value
N= 20 N= 78
Female:male (F:M ratio) 18:2 (9:1) 69:9 (8:1) 1
Age
Range (year) 16–63 14–51
Median (year) 36 25.5 0.003**
SLE duration
Range (year) 1–17 0.25–17




** Highly signiﬁcantly different at p< 0.01.
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aspartate transaminase AST; serum alanine transaminase
ALT; serum total, direct and indirect bilirubin), complete urine
analysis and 24 h urinary proteins. The immunologic tests in-
cluded determination of the antinuclear antibodies (ANA) by
immunoﬂuorescence technique using indirect ﬂuorescence anti-
body kit (ANAFAST, Diasorin; USA) utilizing tissue culture
cells as a substrate for the detection and titration of the circu-
lating antinuclear antibodies in human serum and anti-double
stranded DNA antibody (anti-ds-DNA) using ELISA kit
(Diasorin; USA). It is a quantitative indirect enzyme immuno-
assay for the detection in human serum or plasma of the IgG
and IgM classes of autoantibodies speciﬁc for double-stranded
DNA. IgG and IgM anticardiolipins (aCL) were estimated by
ELISA technique [18,19]. Finally, complement components
(C3 and C4) were estimated by nephelometric method.
2.3. Imaging and other investigations
Chest X-ray and abdominal ultrasound were done for all pa-
tients to assess the chest, liver and kidney status; other imaging
studies were done according to the suspected problems in each
case. Renal biopsy was done; when indicated in selected pa-
tients in each group.
Statistical analysis: Data were processed and analyzed using
the computer program SPSS (The Statistical Package for the
Social Science Program) version 15 for windows (SPSS Inc.,
Chicago, Illinois, USA). For quantitative variables, mean,
range (as a measure of variability), and standard deviation
were used. The median was also presented when considered
appropriate. Frequency and percentage were presented for
qualitative variable and percent for qualitative variables.
Chi-square and Fisher’s exact tests were used to estimate
differences in qualitative variables and Mann–Whitney test
was used to estimate differences in quantitative variables. A
p-value of less than 0.05 was taken to indicate statistical
signiﬁcance.3. Results
3.1. Demographic data of the study group
Ninety-eight patients were included in this study; they repre-
sent all SLE patients presented to the outpatient clinic or
admitted to the rheumatology ward, rheumatology and reha-
bilitation department, Cairo University Hospitals from 1st
July to 31st December 2010. All patients were screened for
HCV antibody. HCV antibodies were present in 20/98
(20.4%) SLE patients (HCV/SLE group), and were absent in
78/98 (79.6%) patients (non-HCV/SLE). HCV-RNA (PCR)
was detected in 8/20 (40% of the HCV antibody positive and
8.2% of the total SLE patients) while the viremia was below
the detection level in 12 (60%) of the positive HCV antibody
patients. Six patients of (HCV/SLE group) were recruited from
the inpatient department (30%) and the rest 14/20 (70%) are
recruited from the outpatient clinic. History of blood transfu-
sion was obtained from 5/20 (25%) patients with HCV/SLE
and from 26/78 (33.3%) patients with non-HCV/SLE. Statisti-
cally signiﬁcant differences were found between the age and
SLE disease duration of patients in both groups. Patients withHCV/SLE were older and were suffering from SLE for a long-
er duration than patients with non-HCV/SLE (Table 1).
3.2. Clinical and laboratory parameters of the study group
Comparison between the clinical features of the disease; classi-
ﬁed according to the system involved in both groups and their
statistical signiﬁcance are shown in (Table 2). Statistically
higher cardiac manifestations and fundus abnormalities were
found in the HCV/SLE group. Carditis was found in 6/20
(30%) and pericardial effusion in 5/20 (25%) of the HCV/
SLE group compared to 10/78 (12.8%) and 12/78 (15.45) in
the non-HCV/SLE respectively. Retinal vasculitis on fundus
examination was detected in 2/20 (10%), optic atrophy in 1/
20 (5%), maculopathy in 1/20 (5%) and papilledema in 1/20
(5%) in the HCV/SLE patients compared to 2/78 (2.6%), 0/
78 (0%), 2/78 (2.6%) and 0/78 (0%) in the non-HCV/SLE pa-
tients, respectively. On the other hand, the mucocutaneous
manifestations were statistically higher in the non HCV/SLE
group. Mucosal ulcers were found in 11/20 (55%), skin rash
in 12/20 (60%), photosensitivity in 14/20 (70%) and alopecia
in 7/20 (35%) in the HCV/SLE patients compared to 46/78
(59%), 54/78 (69.2%), 56/78 (71.8%) and 43/78 (55.1%) in
the non-HCV/SLE patients, respectively. Although there was
no statistical difference as regards the prevalence of the muscu-
loskeletal manifestations between groups, arthralgia and
arthritis tend to be higher in the HCV/SLE patients (95%,
85%) compared to the non-HCV/SLE patients (79.5% and
78.2%), respectively. Abdominal ultrasound showed evidence
of nephropathy in 3/20 patients (15%) in HCV/SLE group ver-
sus 18/78 patients (23.1%) in the non-HCV/SLE group with
no statistically signiﬁcant difference between the groups, and
no cirrhosis was detected in all patients of both groups. Labo-
ratory tests that reﬂected the liver function were not statisti-
cally different between both groups (Table 3).
ANA testing was positive in all our patients. Anti-DNA
positivity was signiﬁcantly lower in patients with HCV/SLE
(p< 0.05). DNA antibodies were found in 11/20 (55%) of pa-
tients in HCV/SLE group compared to 60/78 (76.9%) in pa-
tients with non-HCV/SLE. No statistically signiﬁcant
difference was found between the two groups as regards
ANA titer, complement component positivity or anticardio-
lipin positivity (Table 4).
Table 2 Percentage of clinical features according to the system involved in the two groups.
Clinical features HCV/SLE % Non-HCV/SLE % p-Value
N= 20 N= 78
Constitutional manifestations 16/20 80 69/78 88.5 0.32
Mucocutaneous manifestation 16/20 80 73/78 93.6 0.05*
Vascular manifestations 9/20 45 46/78 58.9 0.26
Musculoskeletal manifestations 20/20 100 76/78 97.4 0.46
Neurological manifestations 12/20 60 39/78 50 0.46
Cardiac manifestations 7/20 35 12/78 15.3 0.04*
Pulmonary manifestations 13/20 65 41/78 52.6 0.31
Hematological manifestations 17/20 85 73/78 93.6 0.21
Fundus abnormalities 5/20 25 4/78 5.1 0.01**
Renal manifestations 4/20 20 15/78 19.2 1
Sicca manifestations 4/20 20 8/78 10.2 0.25
* Signiﬁcantly different at p< 0.05.
** Highly signiﬁcantly different at p< 0.01.
Table 3 Laboratory tests reﬂecting the liver function among
patients of both groups.
Laboratory test HCV/SLE Non-HCV/SLE p-Value
N= 20 N= 78
ALT (U/L)
Median 19.5 21 0.85
Range 8–70 3–185
AST (U/L)
Median 23.5 21.5 0.74
Range 10–75 4–400
Serum total protein (gm/dl)
Median 7.2 6.6 0.46
Range 4.3–8.6 3.9–9.3
Serum albumin (g/dl)
Median 3.7 3.3 0.06
Range 1.9–9.6 2–5.4
GGT (U/L)
Median 35 60 0.40
Range 14–773 8–790
ALP (U/L)
Median 69 62.5 0.19
Range 18–1555 10–338
Total bilirubin (mg/dl)
Median 0.3 0.2 0.97
Range 0.0–1.2 0.0–1.1
Direct bilirubin (mg/dl)
Median 0.0 0.08 0.15
Range 0.0–0.3 0.0–0.7
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study group
On assessing the global disease activity using the SLEDAI
score, 10/20 (50%), 5/20 (25%) and 5/20 (25%) of patients
with HCV/SLE were classiﬁed as mild, moderate, severe lupus
activity respectively; compared to 31/78 (39.7%), 27/78
(34.6%), 19/78 (24.4%) and 1/78 (1.3%) of patients with non
HCV/SLE who were classiﬁed as mild, moderate, severe and
very severe disease respectively. No statistical difference be-
tween the numbers of patients in both groups regarding SLE-
DAI score was detected.Signiﬁcantly lower number of patients in the HCV/SLE
group was on oral steroids than patients in the non-HCV/
SLE group. Table 5 shows the number and percentage of pa-
tients in each group according to the different treatment
modalities used in their management.
4. Discussion
The global prevalence of HCV has been estimated of nearly
3%, with a substantial geographical variation [20]. Many of
this estimates, came from the prevalence rates for HCV infec-
tion in blood donors; however, these prevalence rates deter-
mined from blood donors probably underestimate the HCV
prevalence in the general population [21]. A national US sur-
vey found a prevalence rate more than fourfold higher in gen-
eral population than in voluntary blood donors (1.8% vs.
0.4%), [22,23].
Autoimmunity and viral infections are closely related.
Viruses in general and HCV in particular has been proposed
as possible etiologic or triggering factors of many systemic
autoimmune rheumatic diseases; most of the previous studies
discussed the rheumatic manifestations as a part of the extra-
hepatic manifestations of chronic HCV infection [6,24–28].
In this study we studied the prevalence of HCV antibodies
among patients with SLE and evaluated the impact of the pres-
ence of chronic HCV infection on the SLE disease expression,
through comparison of the demographic data, clinical manifes-
tations and disease activity (SLEDAI score) among patients
with HCV/SLE and non-HCV/SLE.
HCV antibodies were present in 20/98 (20.4%) SLE pa-
tients (HCV/SLE group), and were absent in 78/98 (79.6%)
patients (non-HCV/SLE), of them active viremia (HCV-
RNA) was detected in 8/98 (40% of the HCV antibody posi-
tive and 8.2% of the studied SLE patients) while the viremia
was below the detection level in 12 (60%) of the positive
HCV antibody patients. In a recent study in our department,
HCV antibodies were found in 6.7% among patients with
SLE admitted to the rheumatology ward, Cairo University
Hospitals, Egypt [6]. This ﬁnding indicated that most patients
of SLE and associated anti-HCV antibodies were recruited
from the outpatient clinic and that the association between
HCV infection and SLE does not imply increased SLE disease
Table 4 Comparison between the number and percentage of patients in both groups according to the immunologic proﬁle.
HCV/SLE % Non-HCV/SLE % p-Value
N= 20 N= 78
ANA positivity 20/20 100 78/78 100 –
Anti-ds-DNA positivity 11/20 55 60/78 76.9 0.05*
ANA titer
<1/160 11/20 55 45/78 57.7 0.82
>1/160 9/20 45 33/78 42.3
Complement consumption
Consumed C3 11/20 55 56/78 71.8 0.15
Consumed C4 4/20 20 30/78 38.5 0.12
ACL positivity
IgM 9/20 45 25/78 32.1 0.27
IgG 7/20 35 26/78 33.3 0.88
* Signiﬁcantly different at p< 0.05.
Table 5 Number and percentage of patients according to the drugs used in their management.
Drug SLE/HCV % Non-HCV/SLE % p-Value
N= 20 N= 78
Steroid use 18 90 78 100 0.04*
Antimalarials 17 85 53 67.9 0.13
Azathioprine 9 45 43 55.1 0.41
Cyclophosphamide 4 20 15 19.2 1
Mycophenolate mofetil 0 0 4 5.1 –
* Signiﬁcantly different at p< 0.05.
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rheumatology inpatient’s ward. There are plenty of data
regarding various rheumatic manifestations of HCV infection;
however, this is not the case regarding the prevalence of HCV
among patients with SLE. Anti-HCV antibodies were found in
20.4% and active viremia in 8.25% among lupus patients in
this study. These ﬁgures are much higher than ﬁgures like
1%, 2.3% and 4.8% reported in lupus patients in Israel, cen-
tral Brazil and Iran, respectively which was detected by posi-
tive antibodies and conﬁrmed by PCR [12,29,30]. Antibodies
to HCV were present in 18/134 Spanish patients with SLE
(13%); of them active viremia was detected in 15 SLE patients
(11%) [7].These divergences could be attributed to the variabil-
ity in the prevalence of HCV infection among the different
geographic areas and even to different infection control prac-
tices in these areas.
History of blood transfusion was not different (p= 0.4) be-
tween the two groups; it was obtained from 5/20 (25%) pa-
tients with HCV/SLE and from 26/78 (33.3%) patients with
non-HCV/SLE. Patients with HCV/SLE were older
(p< 0.003) and were suffering from SLE for a longer duration
(p< 0.001) than patients with non-HCV/SLE. In a previous
study on systemic autoimmune disease (SAD) in general, asso-
ciated with HCV, the authors found that SAD-HCV patients
presented a speciﬁc epidemiological proﬁle with a lower fe-
male: male ratio and an older age at diagnosis of SAD [7].
In this study, there was no statistical difference between the
genders of patients of both SLE groups. The most frequent
clinical manifestations in the HCV/SLE patients were the mus-
culoskeletal (100%), hematologic (85%) followed by the
mucocutaneous and constitutional manifestations, each in
80%. On the other hand, the most frequent manifestations inthe non-HCV/SLE patients were the musculoskeletal
(97.4%), followed by the hematologic and mucocutaneous
manifestations, each in 93.6%. Statistically higher cardiac
manifestations (carditis and pericardial effusion) and fundus
examination abnormalities (retinal vasculitis, maculopathy,
optic atrophy and papilledema) were found in the HCV/SLE
group, while the mucocutaneous manifestations (mucosal ul-
cers, skin rash, photosensitivity and alopecia) were statistically
higher in the non HCV/SLE group. Although there was no sta-
tistical difference as regards the prevalence of the musculoskel-
etal manifestations between groups, arthralgia and arthritis
tend to be higher in the HCV/SLE patients (95%, 85%) com-
pared to the non-HCV/SLE patients (79.5% and 78.2%),
(p= 0.1 and 0.7) respectively. Laboratory tests that reﬂected
the liver function were not statistically different between both
groups (Table 3). The absence of signiﬁcant difference in all
the routine laboratory tests of the liver function between the
groups reﬂects the fact that chronic HCV infection may remain
asymptomatic and could present with normal liver functions.
ANA positivity was found in 100% of the patients in both
groups, while anti-DNA antibodies were detected less fre-
quently in patients with HCV/SLE 55% compared to 76.9%
of patients with non-HCV/SLE group (p< 0.05). Similar re-
sults were found in other previous studies [31,32]. No statisti-
cally signiﬁcant difference was found between the two groups
as regards ANA titer, complement component positivity or
anticardiolipin positivity (Table 4). On assessing the global dis-
ease activity using the SLEDAI score, there were no statistical
differences between the numbers of patients with various
grades of score. In addition signiﬁcantly lower number of pa-
tients in the HCV/SLE group was on oral steroids than pa-
tients in the non-HCV/SLE group (Table 5).
14 A. El Garf et al.On conclusion, HCV antibodies and active HCV viremia
were found in 20.4% and 8.2% respectively among SLE pa-
tients. Patients with SLE and concomitant HCV infection were
old aged, have longer disease duration, less frequent mucocu-
taneous manifestations, higher percentage of cardiac manifes-
tations, higher percentage of fundus abnormalities, lower
doses of steroid use, milder disease activity, higher damage in-
dex and less frequent anti-ds-DNA positivity than SLE pa-
tients without concomitant HCV infection.
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